Search

Your search keyword '"Jung, In Young"' showing total 14,262 results
Start Over Author "Jung, In Young"
14,262 results on '"Jung, In Young"'

105. Scalable Solvent-Based Fabrication of Thermo-Responsive Polymer Nanocomposites for Battery Safety Regulation

Author

Li, Mingqian, Xu, Panpan, Lee, Suk-woo, Jung, Bum-young, and Chen, Zheng

Subjects
Physics - Applied Physics
Abstract

Improving lithium-ion batteries (LIBs) safety remains in a challenging task when compared with the tremendous progress made in their performance in recent years. Embedding thermo-responsive polymer switching materials (TRPS) into LIB cells has been proved to be a promising strategy to provide consistent thermal abuse protections at coin-cell level. However, it is unrealistic to achieve large-scale applications without further demonstration in high-capacity pouch cells. Here, we employed tungsten carbide (WC) as a novel conductive filler, and successfully overcame the intrinsic processing difficulty of polyethylene (PE) matrix in a scalable solvent-based method to obtain ultra-thin, uniform, highly conductive TRPS. Moreover, by integrating TRPS directly into LIB electrodes, no extra fabrication facilities or processes are required for making the cells. As a result, multi-layer pouch cells with consistent electrochemical performance and thermal abuse protection function were fabricated using industry relevant manufacturing techniques, which brings TRPS one step further to the real application scenarios., Comment: 20 pages, 6 figures

Published
2021

117. Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma

Author

Kim, Yuna, Jung, Kwan-Young, Kim, Yun Hak, Xu, Pan, Kang, Baeki E., Jo, Yunju, Pandit, Navin, Kwon, Jeongho, Gariani, Karim, Gariani, Joanna, Lee, Junguee, Verbeek, Jef, Nam, Seungyoon, Bae, Sung-Jin, Ha, Ki-Tae, Yi, Hyon-Seung, Shong, Minho, Kim, Kyun-Hwan, Kim, Doyoun, Jung, Hee Jung, Lee, Chang-Woo, Kim, Kwang Rok, Schoonjans, Kristina, Auwerx, Johan, and Ryu, Dongryeol

Published
2024
Full Text
View/download PDF

122. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model.

Author

Tran, Thi-Anh-Thuy, Kim, Young-Hee, Duong, Thi-Hoang-Oanh, Thangaraj, Jaya, Chu, Tan-Huy, Jung, Shin, Kim, In-Young, Moon, Kyung-Sub, Kim, Young-Jin, Lee, Tae-Kyu, Lee, Chul, Yun, Hyosuk, Lee, Je-Jung, Lee, Hyun-Ju, Lee, Kyung-Hwa, and Jung, Tae-Young

Subjects
U87 cell line, bevacizumab, glioblastoma, irinotecan, natural killer cells, Mice, Animals, Humans, Bevacizumab, Glioblastoma, Irinotecan, Ligands, Mice, Inbred NOD, Mice, SCID, Antineoplastic Agents, Killer Cells, Natural
Abstract

Various combination treatments have been considered to attain the effective therapy threshold by combining independent antitumor mechanisms against the heterogeneous characteristics of tumor cells in malignant brain tumors. In this study, the natural killer (NK) cells associated with bevacizumab (Bev) plus irinotecan (Iri) against glioblastoma multiforme (GBM) were investigated. For the experimental design, NK cells were expanded and activated by K562 cells expressing the OX40 ligand and membrane-bound IL-18 and IL-21. The effects of Bev and Iri on the proliferation and NK ligand expression of GBM cells were evaluated through MTT assay and flow cytometry. The cytotoxic effects of NK cells against Bev plus Iri-treated GBM cells were also predicted via the LDH assay in vitro. The therapeutic effect of different injected NK cell routes and numbers combined with the different doses of Bev and Iri was confirmed according to tumor size and survival in the subcutaneous (s.c) and intracranial (i.c) U87 xenograft NOD/SCID IL-12Rγnull mouse model. The presence of injected-NK cells in tumors was detected using flow cytometry and immunohistochemistry ex vivo. As a result, Iri was found to affect the proliferation and NK ligand expression of GBM cells, while Bev did not cause differences in these cellular processes. However, the administration of Bev modulated Iri efficacy in the i.c U87 mouse model. NK cells significantly enhanced the cytotoxic effects against Bev plus Iri-treated GBM cells in vitro. Although the intravenous (IV) injection of NK cells in combination with Bev plus Iri significantly reduced the tumor volume in the s.c U87 mouse model, only the direct intratumorally (IT) injection of NK cells in combination with Bev plus Iri elicited delayed tumor growth in the i.c U87 mouse model. Tumor-infiltrating NK cells were detected after IV injection of NK cells in both s.c and i.c U87 mouse models. In conclusion, the potential therapeutic effect of NK cells combined with Bev plus Iri against GBM cells was limited in this study. Accordingly, further research is required to improve the accessibility and strength of NK cell function in this combination treatment.

Published
2022

123. Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

Author

Kostka, Kristin, Duarte-Salles, Talita, Prats-Uribe, Albert, Sena, Anthony G, Pistillo, Andrea, Khalid, Sara, Lai, Lana YH, Golozar, Asieh, Alshammari, Thamir M, Dawoud, Dalia M, Nyberg, Fredrik, Wilcox, Adam B, Andryc, Alan, Williams, Andrew, Ostropolets, Anna, Areia, Carlos, Jung, Chi Young, Harle, Christopher A, Reich, Christian G, Blacketer, Clair, Morales, Daniel R, Dorr, David A, Burn, Edward, Roel, Elena, Tan, Eng Hooi, Minty, Evan, DeFalco, Frank, de Maeztu, Gabriel, Lipori, Gigi, Alghoul, Hiba, Zhu, Hong, Thomas, Jason A, Bian, Jiang, Park, Jimyung, Roldán, Jordi Martínez, Posada, Jose D, Banda, Juan M, Horcajada, Juan P, Kohler, Julianna, Shah, Karishma, Natarajan, Karthik, Lynch, Kristine E, Liu, Li, Schilling, Lisa M, Recalde, Martina, Spotnitz, Matthew, Gong, Mengchun, Matheny, Michael E, Valveny, Neus, Weiskopf, Nicole G, Shah, Nigam, Alser, Osaid, Casajust, Paula, Park, Rae Woong, Schuff, Robert, Seager, Sarah, DuVall, Scott L, You, Seng Chan, Song, Seokyoung, Fernández-Bertolín, Sergio, Fortin, Stephen, Magoc, Tanja, Falconer, Thomas, Subbian, Vignesh, Huser, Vojtech, Ahmed, Waheed-Ul-Rahman, Carter, William, Guan, Yin, Galvan, Yankuic, He, Xing, Rijnbeek, Peter R, Hripcsak, George, Ryan, Patrick B, Suchard, Marc A, and Prieto-Alhambra, Daniel

Subjects
Clinical Research, Infectious Diseases, Prevention, 2.4 Surveillance and distribution, Aetiology, Good Health and Well Being, OHDSI, OMOP CDM, descriptive epidemiology, real world data, real world evidence, open science, Clinical Sciences, Public Health and Health Services
Abstract

PurposeRoutinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) Characterizing Health Associated Risks and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.Patients and methodsWe conducted a descriptive retrospective database study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub. We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19, and 113,627 hospitalized with COVID-19 requiring intensive services.ResultsWe aggregated over 22,000 unique characteristics describing patients with COVID-19. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts and are readily available online. Globally, we observed similarities in the USA and Europe: more women diagnosed than men but more men hospitalized than women, most diagnosed cases between 25 and 60 years of age versus most hospitalized cases between 60 and 80 years of age. South Korea differed with more women than men hospitalized. Common comorbidities included type 2 diabetes, hypertension, chronic kidney disease and heart disease. Common presenting symptoms were dyspnea, cough and fever. Symptom data availability was more common in hospitalized cohorts than diagnosed.ConclusionWe constructed a global, multi-centre view to describe trends in COVID-19 progression, management and evolution over time. By characterising baseline variability in patients and geography, our work provides critical context that may otherwise be misconstrued as data quality issues. This is important as we perform studies on adverse events of special interest in COVID-19 vaccine surveillance.

Published
2022

124. Publisher Correction: FOXO1 is a master regulator of memory programming in CAR T cells

Author

Doan, Alexander E., Mueller, Katherine P., Chen, Andy Y., Rouin, Geoffrey T., Chen, Yingshi, Daniel, Bence, Lattin, John, Markovska, Martina, Mozarsky, Brett, Arias-Umana, Jose, Hapke, Robert, Jung, In-Young, Wang, Alice, Xu, Peng, Klysz, Dorota, Zuern, Gabrielle, Bashti, Malek, Quinn, Patrick J., Miao, Zhuang, Sandor, Katalin, Zhang, Wenxi, Chen, Gregory M., Ryu, Faith, Logun, Meghan, Hall, Junior, Tan, Kai, Grupp, Stephan A., McClory, Susan E., Lareau, Caleb A., Fraietta, Joseph A., Sotillo, Elena, Satpathy, Ansuman T., Mackall, Crystal L., and Weber, Evan W.

Published
2024
Full Text
View/download PDF

125. Evolution of the Tumor Microenvironment toward Immune-Suppressive Seclusion during Brain Metastasis of Breast Cancer: Implications for Targeted Therapy.

Author

Noh, Myung-Giun, Kim, Sung, Kim, Yeong, Jung, Tae-Young, Jung, Shin, Rhee, Joon-Haeng, Lee, Jae-Hyuk, Lee, Ji-Shin, Cho, Jae-Ho, Moon, Kyung-Sub, Park, Hansoo, and Lee, Kyung-Hwa

Subjects
breast neoplasms, gene expression profiling, immunohistochemistry, neoplasm metastasis, tumor microenvironment
Abstract

Breast cancer (BC) is the second most common solid malignant tumor that metastasizes to the brain. Despite emerging therapies such as immunotherapy, whether the tumor microenvironment (TME) in breast cancer brain metastasis (BCBM) has potential as a target of new treatments is unclear. Expression profiling of 770 genes in 12 pairs of primary BC and matched brain metastasis (BM) samples was performed using the NanoString nCounter PanCancer IO360TM Panel. Immune cell profiles were validated by immunohistochemistry (IHC) in samples from 50 patients with BCBM. Pathway analysis revealed that immune-related pathways were downregulated. Immune cell profiling showed that CD8+ T cells and M1 macrophages were significantly decreased, and M2 macrophages were significantly increased, in BM compared to primary BC samples (p = 0.001, p = 0.021 and p = 0.007, respectively). CCL19 and CCL21, the top differentially expressed genes, were decreased significantly in BM compared to primary BC (p < 0.001, both). IHC showed that the CD8+ count was significantly lower (p = 0.027), and the CD163+ and CD206+ counts were higher, in BM than primary BC (p < 0.001, both). A low CD8+ T cell count, low CD86+ M1 macrophage count, and high M2/M1 macrophage ratio were related to unfavorable clinical outcomes. BC exhibits an immunosuppressive characteristic after metastasis to the brain. These findings will facilitate establishment of a treatment strategy for BCBM based on the TME of metastatic cancer.

Published
2021

150. Vocoder-free End-to-End Voice Conversion with Transformer Network

Author

Kim, June-Woo, Jung, Ho-Young, and Lee, Minho

Subjects
Electrical Engineering and Systems Science - Audio and Speech Processing, Computer Science - Machine Learning, Computer Science - Sound, Statistics - Machine Learning
Abstract

Mel-frequency filter bank (MFB) based approaches have the advantage of learning speech compared to raw spectrum since MFB has less feature size. However, speech generator with MFB approaches require additional vocoder that needs a huge amount of computation expense for training process. The additional pre/post processing such as MFB and vocoder is not essential to convert real human speech to others. It is possible to only use the raw spectrum along with the phase to generate different style of voices with clear pronunciation. In this regard, we propose a fast and effective approach to convert realistic voices using raw spectrum in a parallel manner. Our transformer-based model architecture which does not have any CNN or RNN layers has shown the advantage of learning fast and solved the limitation of sequential computation of conventional RNN. In this paper, we introduce a vocoder-free end-to-end voice conversion method using transformer network. The presented conversion model can also be used in speaker adaptation for speech recognition. Our approach can convert the source voice to a target voice without using MFB and vocoder. We can get an adapted MFB for speech recognition by multiplying the converted magnitude with phase. We perform our voice conversion experiments on TIDIGITS dataset using the metrics such as naturalness, similarity, and clarity with mean opinion score, respectively., Comment: Work in progress

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results